Series Embark SERIES EMBARK
Here are some of the many stories about Kyoto-iCAP's relationship with the companies we support.
![#17 Spun off from Takeda, incorporating university wisdom to develop new anti-cancer drugs](https://www.kyoto-unicap.co.jp/cms/wp-content/uploads/emberk_017-1.jpg)
Chordia Therapeutics, Inc.
![#14 Paving the way for a sustainable future energy society with innovative energy storage technology](https://www.kyoto-unicap.co.jp/cms/wp-content/uploads/emberk_014.jpg)
CONNEXX SYSTEMS Co., Ltd.
![#13 "iPS Drug Discovery" searches for effective drugs for intractable<br> diseases for which there is no cure](https://www.kyoto-unicap.co.jp/cms/wp-content/uploads/emberk_013.jpg)
Stem Cell & Device Laboratory Inc.
![#10 iPS cell therapy aims to revolutionize treatment of chronic kidney disease (CKD)](https://www.kyoto-unicap.co.jp/cms/wp-content/uploads/embark_010.jpg)
Rege Nephro Co., Ltd.
STORIES
Here are some of the many stories about Kyoto-iCAP's relationship with the companies we support.
Chordia Therapeutics, Inc.
CONNEXX SYSTEMS Co., Ltd.
Stem Cell & Device Laboratory Inc.
Rege Nephro Co., Ltd.
Please feel free to contact us if you have any questions or concerns.
Inquiry Form